ATE517090T1 - Piperidinsulfonamidderivate - Google Patents

Piperidinsulfonamidderivate

Info

Publication number
ATE517090T1
ATE517090T1 AT09711149T AT09711149T ATE517090T1 AT E517090 T1 ATE517090 T1 AT E517090T1 AT 09711149 T AT09711149 T AT 09711149T AT 09711149 T AT09711149 T AT 09711149T AT E517090 T1 ATE517090 T1 AT E517090T1
Authority
AT
Austria
Prior art keywords
sulphonamide derivatives
formula
piperidine
compounds
piperidine sulphonamide
Prior art date
Application number
AT09711149T
Other languages
English (en)
Inventor
Henner Knust
Matthias Nettekoven
Emmanuel Pinard
Olivier Roche
Mark Rogers-Evans
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE517090T1 publication Critical patent/ATE517090T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/96Sulfur atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Addiction (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
AT09711149T 2008-02-12 2009-02-02 Piperidinsulfonamidderivate ATE517090T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08151328 2008-02-12
PCT/EP2009/051135 WO2009100994A1 (en) 2008-02-12 2009-02-02 Piperidine sulfonamide derivatives

Publications (1)

Publication Number Publication Date
ATE517090T1 true ATE517090T1 (de) 2011-08-15

Family

ID=40651273

Family Applications (1)

Application Number Title Priority Date Filing Date
AT09711149T ATE517090T1 (de) 2008-02-12 2009-02-02 Piperidinsulfonamidderivate

Country Status (13)

Country Link
US (3) US8202888B2 (de)
EP (1) EP2252587B1 (de)
JP (1) JP5346043B2 (de)
KR (1) KR101229603B1 (de)
CN (1) CN101918361B (de)
AT (1) ATE517090T1 (de)
AU (1) AU2009214244B2 (de)
BR (1) BRPI0907627A2 (de)
CA (1) CA2713713C (de)
ES (1) ES2367341T3 (de)
IL (1) IL206615A (de)
MX (1) MX2010007968A (de)
WO (1) WO2009100994A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101802726B1 (ko) * 2010-08-24 2017-11-29 액테리온 파마슈티칼 리미티드 오렉신 수용체 안타고니스트로서의 프롤린 술폰아미드 유도체
US9440982B2 (en) 2012-02-07 2016-09-13 Eolas Therapeutics, Inc. Substituted prolines/piperidines as orexin receptor antagonists
RU2014136339A (ru) 2012-02-07 2016-03-27 Иолас Терапьютикс, Инк. Замещенные пролины/пиперидины как антагонисты орексиновых рецепторов
EP3180332B1 (de) 2014-08-13 2021-10-27 Eolas Therapeutics Inc. Difluorpyrrolidine als orexinrezeptormodulatoren
KR102738491B1 (ko) 2016-02-12 2024-12-03 아스트라제네카 아베 오렉신 수용체 조정제로서의 할로-치환된 피페리딘
US12187737B2 (en) 2019-06-04 2025-01-07 Hager Biosciences, Llc Imidazolo derivatives, compositions and methods as orexin antagonists

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0115862D0 (en) * 2001-06-28 2001-08-22 Smithkline Beecham Plc Compounds
CA2513921C (en) * 2003-02-13 2009-07-21 Guardian Industries Corp. Coated articles with nitrided layer and methods of making same
EP1758882A4 (de) * 2004-06-24 2008-01-23 Incyte Corp Amidverbindungen und ihre verwendung als arzneimittel
BRPI0609062A2 (pt) * 2005-03-03 2010-02-17 F. Hofmann-La Roche Ag composição farmacêutica, compostos, método para o tratamento terapêutico e/ou profilático de enfermidades que são moduladas por inibidores de deidrogenase de hidroxiesteróide-11ß e utilização dos compostos
WO2006127550A1 (en) * 2005-05-23 2006-11-30 Merck & Co., Inc. Proline bis-amide orexin receptor antagonists
ES2349160T3 (es) * 2006-01-23 2010-12-28 F. Hoffmann-La Roche Ag Derivados de la ciclohexil sulfonamida con actividad frente a los receptores h3.
CN101432285A (zh) * 2006-04-26 2009-05-13 埃科特莱茵药品有限公司 作为食欲素受体拮抗剂的吡唑并-四氢吡啶衍生物
AU2007272795A1 (en) * 2006-07-14 2008-01-17 Merck & Co., Inc. 2-substituted proline bis-amide orexin receptor antagonists

Also Published As

Publication number Publication date
IL206615A0 (en) 2010-12-30
US8691846B2 (en) 2014-04-08
CN101918361B (zh) 2014-05-28
KR20100111709A (ko) 2010-10-15
KR101229603B1 (ko) 2013-02-04
CN101918361A (zh) 2010-12-15
JP5346043B2 (ja) 2013-11-20
US20090203736A1 (en) 2009-08-13
AU2009214244B2 (en) 2013-02-07
CA2713713C (en) 2016-05-24
WO2009100994A1 (en) 2009-08-20
EP2252587B1 (de) 2011-07-20
EP2252587A1 (de) 2010-11-24
US20130217729A1 (en) 2013-08-22
MX2010007968A (es) 2010-08-04
BRPI0907627A2 (pt) 2015-07-21
US8202888B2 (en) 2012-06-19
ES2367341T3 (es) 2011-11-02
US20120238602A1 (en) 2012-09-20
JP2011511822A (ja) 2011-04-14
CA2713713A1 (en) 2009-08-20
IL206615A (en) 2015-10-29
AU2009214244A1 (en) 2009-08-20

Similar Documents

Publication Publication Date Title
CY1108230T1 (el) Παραγωγα 2-(1η-ινδολυλοσουλφανυλ)-βενζυλαμινης ως ssri
CY1120832T1 (el) Τροποποιητες πυρηνικης μεταφορας και χρησεις αυτων
ATE538100T1 (de) Aminotetrahydroindazoloessigsäuren
MY147649A (en) Benzimidazole derivatives useful in treatment of vallinoid receptor trpv1 related disorders
CR11757A (es) Compuestos de triazina como inhibidores mtor y quinasa pi3
MA32272B1 (fr) Inhibiteurs de raf de pyrazole [3,4-b]pyridine
ATE483707T1 (de) 2-cyclopropylthiazolderivate
EP2288260A4 (de) Triazolopyridin-jak-hemmer-verbindungen und verfahren
ATE493386T1 (de) Trans-3-aza-bicyclo-ä3.1.0ü-hexan-derivate
IL206615A0 (en) Piperidine sulfonamide derivatives
CR8928A (es) Derivados arilsulfonilestilbeno para tratamiento de insomnio y afecciones relacionadas
MX2010006565A (es) Derivados de benzimidazol sustituido por carboxilo o hidroxilo.
BR112014023384A2 (pt) inibidores de bace de di-hidro-tiazina e di-hidro-oxazina espirocíclicos, e composições e usos dos mesmos
MA32544B1 (fr) Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique
WO2010018109A3 (en) Substituted aminotetralines
CO6480931A2 (es) Sulfonamidas heterocíclicas, usos y composiciones farmacéuticas de las mismas.
NO20083058L (no) Cykloheksylsulfonamidderivater med H3 reseptor aktivitet
EA201100358A1 (ru) Дабигатран для чрескожной хирургической катетеризации сердца
MX2009009121A (es) Aminoamidas como antagonistas de orexina.
MX350862B (es) Acidos de piperidinil naftilacetico.
MX2010005047A (es) Inhibidores de aldh-2 en el tratamiento de enfermedades psiquiatricas.
CL2009000876A1 (es) Forma cristalina maleato de orvepitant anhidro; composicion farmaceutica; y su uso para tratar trastornos del sistema nervioso central, tales como depresion, ansiedad, trastornos de estres postraumatico, emesis y/o trastornos del sueno.
ATE524446T1 (de) Sulfatierte benzimidazolon-derivate mit gemischter serotonin-rezeptor-affinität
UA99638C2 (ru) Оксазолидиноны для лечения и/или профилактики сердечной недостаточности
EA201001828A1 (ru) Способ синтеза производных 3,6-дигидро-1,3,5-триазина

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 2252587

Country of ref document: EP